Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04388033CT.gov Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primitive Neuroectodermal Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Interleukin-12 (this asset) | Second Affiliated Hospital, School of Medicine, Zhejiang University | P1/2 | CCC · 48 |
| Tasadenoturev | DNAtrix, Inc. | P2 | B |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
| Pembrolizumab | DNAtrix, Inc. | P2 | B |
| Genistein | University of Virginia | P2 | CCC |
| Belzutifan | José Claudio Casali da Rocha | P2 | CCC |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P2 | CCC |
| Nivestim | St. Jude Children's Research Hospital | P1 | CCC |
| Pralsetinib, Trans- | Hoffmann-La Roche | P1/2 | CCC |
+13 more in the Primitive Neuroectodermal Tumor cohort
Other indications for Interleukin-12
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Immune System Disorder | — | P1/2 | CCC · 48 |
| Neuroepithelial Neoplasm | — | P1/2 | CCC · 48 |
| Nervous System Neoplasm | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Interleukin-12 in Primitive Neuroectodermal Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/interleukin-12-primitive-neuroectodermal-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →